Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis
NCT ID: NCT00141830
Last Updated: 2020-09-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
159 participants
INTERVENTIONAL
2005-08-31
2006-10-19
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose-finding of Multiple Dose of BT061 in Patients With Active Rheumatoid Arthritis Incompletely Controlled on Stable Methotrexate (MTX)
NCT01481493
A Study to Assess CH1504 in Patients With Active Rheumatoid Arthritis
NCT00658047
ATI-450 Plus Methotrexate (MTX) Versus Placebo Plus MTX in Participants With Moderate to Severe Active Rheumatoid Arthritis (RA)
NCT05279417
An Efficacy And Safety Study of CNTO 6785 In Participants With Active Rheumatoid Arthritis Despite Methotrexate Therapy
NCT01909427
Safety and Effectiveness Study of RWJ-445380 Cathepsin-S Inhibitor in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy
NCT00425321
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Methotrexate plus ERB-041 for 12 weeks
Placebo for 12 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Rheumatoid arthritis onset after 16 years of age
Exclusion Criteria
* History of male or female reproductive system cancer
* Clinically significant laboratory abnormalities
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Largo, Florida, United States
Palm Harbor, Florida, United States
Sarasota, Florida, United States
Boise, Idaho, United States
Kansas City, Kansas, United States
Frederick, Maryland, United States
Albuquerque, New Mexico, United States
Charlotte, North Carolina, United States
Duncansville, Pennsylvania, United States
Austin, Texas, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Spokane, Washington, United States
La Crosse, Wisconsin, United States
Penticton, British Columbia, Canada
Newmarket, Ontario, Canada
Toronto, Ontario, Canada
Montreal, Quebec, Canada
Trois-Rivières, Quebec, Canada
Saskatoon, Saskatchewan, Canada
Québec, , Canada
Békéscsaba, , Hungary
Budapest, , Hungary
Veszprém, , Hungary
Brescia, , Italy
Genova, , Italy
Pavia, , Italy
Roma, , Italy
Siena, , Italy
Jalisco, Guadalajara, Mexico
Delegacion Cuahutemoc, , Mexico
Andalucia, Andalusia, Spain
Castilla La Mancha, , Spain
Comunidad Valenciana, , Spain
Madrid, , Spain
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Roman-Blas JA, Castaneda S, Cutolo M, Herrero-Beaumont G. Efficacy and safety of a selective estrogen receptor beta agonist, ERB-041, in patients with rheumatoid arthritis: a 12-week, randomized, placebo-controlled, phase II study. Arthritis Care Res (Hoboken). 2010 Nov;62(11):1588-93. doi: 10.1002/acr.20275. Epub 2010 Jun 15.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B2381010
Identifier Type: OTHER
Identifier Source: secondary_id
2005-001319-23
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
3142A1-202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.